Nkarta Inc (NKTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nkarta Inc (NKTX) has a cash flow conversion efficiency ratio of -0.069x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.65 Million) by net assets ($312.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nkarta Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Nkarta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Nkarta Inc (NKTX) total liabilities for a breakdown of total debt and financial obligations.
Nkarta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nkarta Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akenerji Elektrik Uretim AS
IS:AKENR
|
0.044x |
|
Flutter Entertainment PLC
LSE:FLTR
|
0.044x |
|
Usun Technology Co Ltd
TWO:3498
|
0.058x |
|
Mieco Chipboard Bhd
KLSE:5001
|
0.054x |
|
Yapi Kredi Koray Gayrimenkul Yatirim Ortakligi AS
IS:KGYO
|
0.147x |
|
Cristales
SN:CRISTALES
|
-0.025x |
|
Mosel Vitelic Inc
TW:2342
|
-0.011x |
|
Core Molding Technologies Inc
NYSE MKT:CMT
|
0.032x |
Annual Cash Flow Conversion Efficiency for Nkarta Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nkarta Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Nkarta Inc (NKTX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $312.32 Million | $-88.70 Million | -0.284x | -16.22% |
| 2024-12-31 | $407.98 Million | $-99.70 Million | -0.244x | +22.49% |
| 2023-12-31 | $273.29 Million | $-86.16 Million | -0.315x | -105.87% |
| 2022-12-31 | $372.21 Million | $-57.00 Million | -0.153x | +43.42% |
| 2021-12-31 | $250.97 Million | $-67.93 Million | -0.271x | -99.84% |
| 2020-12-31 | $321.22 Million | $-43.51 Million | -0.135x | -118.79% |
| 2019-12-31 | $-25.48 Million | $-18.37 Million | 0.721x | -24.97% |
| 2018-12-31 | $-5.40 Million | $-5.18 Million | 0.961x | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more